Avient's New CEO Turns the Page From Deleveraging to Acceleration
A record third quarter, the first buyback since 2022, and a fresh supply-chain review signal a strategic handoff—just as the old playbook was working.
AVNT · Earnings Call · 2026-11-04
Avient's third quarter looked like a victory lap for the old playbook. Adjusted EPS of $0.86 beat by $0.06; organic sales rose 10.6%; adjusted EBITDA margin reached a third-quarter record 17.3%, up 80 basis points; and management raised full-year EPS, EBITDA, and free-cash-flow guidance. The stock has noticed: shares are up 29.5% in the last 90 trading days, though they remain roughly 21% below the 2021 peak. Yet the loudest signal on the call was not the beat. It was Mike Frank, three weeks into the CEO job, telling investors the board did not hire him to fix a broken strategy.
This is not a turnaround story, and the Board believes our strategy is well defined. However, they also believe we have opportunities to accelerate the growth trajectory of our business which is core to my mandate.
That distinction matters. Avient's prior era, under Ashish Khandpur, was about repairing the balance sheet, pricing ahead of raw materials, and coaxing growth out of a small set of growth vectors while the core sputtered. The new message is acceleration.
The beat is real, but the mix is still price-led
Operationally, the quarter was genuinely broad based: both segments and every region grew. Color Additives & Ink organic sales rose 8%, EBITDA 15%, and margin reached 20.1%. Specialty Engineered Materials organic sales rose 15%, with eight of nine end markets growing and margin at 21.3%. Functional additives—chemical foaming agents for light weighting and barrier additives for packaging—did much of the mix work. But look under the hood: total volume grew only about 1%. “Total volume growth was approximately 1% in the quarter. With price and mix contributing the balance of the organic growth.” — Giuseppe Di Salvo, CFO · 2026-11-04 That is high-quality price/mix, not a demand snapback. Europe remained the soft spot; Asia grew 20% after 18% in the second quarter.
The last filed quarter showed total revenue of $917 million, up 6% year over year, with gross margin of 33.5%, up 1.5 points year over year. The Q3 call extends that margin story; it does not yet prove a volume-led recovery.
Healthcare normalizes, but the new to-do list is execution
Healthcare is the clearest example of a company-specific cycle turning. For two quarters, management flagged inventory rebalancing in drug-delivery pens and remote monitoring. In Q3, SEM healthcare returned to double-digit growth. Frank still acknowledged some rebalancing in injectable pens, but the broader message was that healthcare—about 8% of sales in each segment—remains a growth vector. “Health care is one of our growth vectors, and we saw another good quarter in health care.” — Michael J. Frank, CEO · 2026-11-04 That is a relief, but it is a normalization story, not a new secular theme.
The new CEO's early diagnosis is execution, not portfolio. He named three opportunities: scale innovation across multiple customers simultaneously rather than sequentially; sell the breadth of the two segments to customers as one Avient; and take a fresh look at the end-to-end supply chain. The third is the most concrete. “We do have a lot of plants ... we will look at opportunities to potentially accelerate that.” — Michael J. Frank, CEO · 2026-11-04 Avient has discussed footprint optimization for years as one of several productivity buckets. What is new is a CEO saying the company may accelerate that work and use procurement scale and AI tools to attack cost of service. He cautioned it is too early to announce a restructuring. Investors should treat it as a 2027 lever, not a Q4 event. The phrase early innings is doing a lot of work in this story.
Capital allocation is the clearest handoff
Avient has paid down $250 million of debt over the last 18 months and expects to exit 2026 at 2.2-2.3x net leverage, down from 2.6x. That improvement has opened the door to the first share repurchase since 2022: 281,000 shares for about $10.9 million in the fourth quarter. The CFO framed the new math plainly. “With over $200 million of free cash flow, we need about $100 million a year to fund and sustain our dividend ... That leaves excess cash of $100 million at least a year.” — Giuseppe Di Salvo, CFO · 2026-11-04 That is a real shift from the prior script. In February 2026, Khandpur said “in the near term, you can expect us to keep paying the debt versus buyback.” — Ashish K. Khandpur, Chief Executive Officer · 2026-02-12 In November 2025, the CFO said if leverage were closer to 2.5x, Avient would be buying back shares. Now it is. The buyback is small, but the signal is not: the board is comfortable shifting from balance-sheet repair to optionality.
Frank also conceded Avient needs to rebuild its M&A muscle after years of deleveraging, but he explicitly ruled out meaningful near-term deals. M&A will compete with debt reduction and buybacks. That is a more balanced capital allocation message than the prior no-M&A, debt-first stance, even if the actual dollars are still modest.
What management stopped leading with
One telling omission: the data center and high performance computing theme that Khandpur showcased in May 2026 is no longer a headline. On that call he sized a roughly $2 billion addressable opportunity across data center and electronics, with the business approaching $100 million. “The actual addressable opportunity with our current portfolio ... close to $1 billion for the data center and electronics part.” — Ashish Khandpur, President and CEO · 2026-05-07 On this call, high-performance computing electronics appears mainly in Q&A as a driver of Asian packaging and telecom. The global tape may explain the reticence: AI data center and high-bandwidth memory themes have been among the worst-performing clusters over the last 30 and 90 days. Avient is not abandoning the theme, but the new CEO is not leading with it either. For a company trying to prove it can accelerate core growth, that is a disciplined choice—though it also means Avient gets less credit if the AI infrastructure trade reaccelerates.
The quarter itself was strong enough to justify the raised guide. The strategic question is whether Avient can convert price/mix and productivity into volume-led sales growth before the old margin levers run out. Frank's answer is a supply-chain and innovation reset, plus a more balanced capital allocation. The proof will come with the FY2027 operating plan in February. For now, the market is paying for the promise: a 29.5% 90-day run into a new CEO's first print. The risk is that the acceleration mandate arrives just as the easy price/mix tailwind fades and Europe stays muted. The opportunity is that a fresher, more offensive Avient deserves a better multiple than the one it has carried since the 2021 peak.